(Q33426973)

English

Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Edwin M Posadas

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rafi S Ahmed

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Theodore Karrison

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Russell Z Szmulewitz

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Peter H O'Donnell

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James L Wade

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James Shen

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Murali Gururajan

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Margarit Sievert

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Walter M Stadler

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

23 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

76

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

286-293

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2014

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

NanoVelcro Chip for CTC enumeration in prostate cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Differential transformation capacity of Src family kinases during the initiation of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Invasive prostate carcinoma driven by c-Src and androgen receptor synergy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Fyn: a novel molecular target in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

VEGF inhibitors and prostate cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

FYN is overexpressed in human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4904773

21 June 2018

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23119

21 January 2018

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23119

21 January 2018

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23119

21 January 2018

Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23119

21 January 2018

The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23119

21 January 2018

Clinical characteristics and prognostic factors of prostate cancer with liver metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/26493492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26493492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/PROS.23119

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33426973&oldid=1856120543"